 |
|
 |
| |
Directory
Guest(s) Dr. Brad Thompson, Ph.D. Topic Info Dr. Brad Thompson has provided leadership to various organizations within the biotechnology sector for more than 20 years, He is currently Chairman, President and Chief Executive Officer of Oncolytics Biotech Inc. Oncolytics Biotech Inc. was formed in 1998 to develop its proprietary product, REOLYSIN®, as a potential therapeutic for a wide variety of human cancers. Oncolytics has completed six clinical trials with REOLYSIN® in Canada, the U.K. and the U.S. and is currently conducting or has approval to commence seven Phase I or Phase II REOLYSIN® trials in the U.K. and the U.S
|
|
 |
|
 |
|
|
Archives 
